IP Library › Granted Patent US 7,897,641
Granted Patent B2
US 7,897,641 · App. 10/220,185 · Granted Mar 1, 2011

Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,897,641
App. No.
10/220,185
Granted
Mar 1, 2011
Kind
B2
Abstract

A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.

Claims (30)

1. A combination composition consisting of:

(a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; and

(b) an amino acid selected from the group consisting of glycine, alanine, arginine and serine or the pharmacologically acceptable salts thereof or mixtures thereof

wherein the weight ratio (a):(b) ranges from 10:1 to 1:10.

2. A combination composition consisting of:

(a) propionyl L-carnitine or a pharmacologically acceptable salt thereof and a carnitine selected from the group consisting of L-carnitine, valeryl L-carnitine, isovaleryl L-carnitine and butyryl L-carnitine or their pharmacologically acceptable salts or mixtures thereof; and

(b) an amino acid selected from the group consisting of glycine, alanine, arginine and serine or the pharmacologically acceptable salts thereof or mixtures thereof

wherein the weight ratio (a):(b) ranges from 10:1 to 1:10.

3. The composition of claim 1 , wherein the weight ratio (a):(b) ranges from 5:1 to 1:5.

4. The composition of claim 1 wherein the pharmacologically acceptable salt is selected from the group consisting of: chloride; bromide; iodide; aspartate, acid aspartate; citrate, acid citrate; tartrate; phosphate, acid phosphate; fumarate, acid fumarate; glycerophosphate; glucose phosphate; lactate; maleate, acid maleate; mucate; orotate; oxalate; acid oxalate; sulphate, acid sulphate; trichloroacetate; trifluoroacetate and methane suiphonate.

5. The composition of claim 1 , orally administrable, in the form of a dietary supplement.

6. The composition of claim 1 , orally, parenterally, rectally, sublingually or transdermally administrable, in the form of a medicament.

7. A method for treating cellular and tissue alterations due to the toxic effects of immunosuppressants which comprises administering to a subject in need thereof a combination composition of claim 1 .

8. The method of claim 7 wherein the immunosuppressants are selected from the group consisting of cyclosporin-A and tacrolimus.

9. The composition of claim 1 as a dietary supplement in solid, semisolid or liquid form.

10. The composition of claim 1 , in solid, semi-solid or liquid form.

11. The dietary supplement of claim 9 , in the form of tablets, lozenges, pills, capsules, granulates or syrups.

12. The composition of claim 10 , in the form of tablets, lozenges, pills, capsules, granulates, syrups, vials or drops.

13. A method for the treatment of nephrotoxic, vasculotoxic or cytotoxic lesions brought about by the use of immunosuppressants selected from the group consisting of cyclosporin-A and tacrolimus, which comprises administering to a subject in need thereof a combination composition of claim 1 .

14. A method for treating cellular and tissue alterations of exogenous, toxic or metabolic origin and decreasing the toxic effects of immunosuppressants which comprises administering to a subject in need thereof a combination composition of claim 1 .

15. A method for the treatment of nephrotoxic, vasculotoxic or cytotoxic lesions brought about by the use of immunosuppressants selected from the group consisting of cyclosporin-A and tacrolimus, which comprises administering to a subject in need thereof a combination composition of claim 1 ,

wherein the weight ratio of (a):(b) is 1:1.

16. A method for treating cellular and tissue alterations of exogenous, toxic or metabolic origin and decreasing the toxic effects of immunosuppressants which comprises administering to a subject in need thereof a combination composition of claim 1 ,

wherein the weight ratio of (a):(b) is 1:1.

17. A combination composition consisting of:

(a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; and

(b) an amino acid selected from the group consisting of glycine, alanine, arginine and serine or the pharmacologically acceptable salts thereof or mixtures thereof; and

(c) vitamins, coenzymes, mineral substances, aminoacids or antioxidants

wherein the weight ratio (a):(b) ranges from 10:1 to 1:10.

18. A method for the treatment of nephrotoxic lesions brought about by the use of immunosuppressants selected from the group consisting of cyclosporin-A and tacrolimus, which comprises administering to a subject in need thereof a combination composition of claim 1 .